Impact of BRAF and RAS mutations on first-line efficacy of...

European Journal of Cancer 2017 / 07 Vol. 79

Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study

Stintzing, S., Miller-Phillips, L., Modest, D.P., Fischer von Weikersthal, L., Decker, T., Kiani, A., Vehling-Kaiser, U., Al-Batran, S.-E., Heintges, T., Kahl, C., Seipelt, G., Kullmann, F., Stauch, M
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
79
Language:
english
Journal:
European Journal of Cancer
DOI:
10.1016/j.ejca.2017.03.023
Date:
July, 2017
File:
PDF, 999 KB
english, 2017
Conversion to is in progress
Conversion to is failed